Real-world experience with Ropeginterferon-alpha 2b (Besremi) in Philadelphia-negative myeloproliferative neoplasms.

CONCLUSION: Conclusively, observed signs of efficacy and safety in our real-world experience prove Ropeg as a promising option for the treatment of MPN.
PMID: 32873465 [PubMed - as supplied by publisher]

Source: J Formos Med Assoc - August 28, 2020 Category: General Medicine Authors: Huang CE, Wu YY, Hsu CC, Chen YJ, Tsou HY, Li CP, Lai YH, Lu CH, Chen PT, Chen CC Tags: J Formos Med Assoc Source Type: research